Core Insights - Hainan Boao Lecheng International Medical Tourism Pilot Zone is becoming a crucial link between rare disease drug companies and patients through policy iterations, insurance collaboration, and multi-dimensional empowerment [1] Policy Iteration - The policy framework for rare disease drug assurance in Lecheng has evolved through three versions: - Version 1.0 focuses on introducing licensed drugs and devices to allow some patients to access urgently needed medications [2] - Version 2.0 allows the use of real-world data from rare disease drugs for expedited domestic approval [2] - Version 3.0 expands the coverage to include special medical foods, health products, and new biomedical technologies [2] Special Drug Insurance - Lecheng has launched a special drug insurance plan to significantly reduce the financial burden on patients, with premiums starting at 49 yuan and coverage up to 2 million yuan for 120 types of global special drugs and 10 types of imported devices [3] Future Initiatives - Lecheng aims to strengthen the connection between rare disease drug companies and patients by leveraging special drug policies and introducing more special medical foods [4] - The zone has received approval for biomedical new technology policies, allowing clinical research and application transformation for technologies that have completed Phase II trials [4] - The initiative includes collaboration with the National Medical Products Administration and the National Healthcare Security Administration to expedite drug registration and insurance access [4]